- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Carbapenemase.
Displaying page 1 of 1.
EudraCT Number: 2012-000726-21 | Sponsor Protocol Number: D4280C00006 | Start Date*: 2012-09-11 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant G... | ||||||||||||||||||
Medical condition: cUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) HU (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000449-65 | Sponsor Protocol Number: Desprobioxa | Start Date*: 2014-07-07 | |||||||||||
Sponsor Name:Fundacion para La Investigación Biomédica Hospital Universitario La Paz (FIBHULP) | |||||||||||||
Full Title: PILOT STUDY OF the EFFECTIVENESS of PROBIOTICS and LACTITOL for the INTESTINAL Decolonization of PEOPLE CARRIERS of Klebsiella pneumoniae producers of carbapenemase OXA-48 TYPE: STUDIO DESPROBIOXA | |||||||||||||
Medical condition: Intestinal Decolonization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003727-22 | Sponsor Protocol Number: CER13266 | Start Date*: 2015-05-26 | |||||||||||||||||||||
Sponsor Name:Geneva University Hospitals | |||||||||||||||||||||||
Full Title: A randomized controlled multicenter trial of a five day course of oral colistin and neomycin followed by restoration of the gut microbiota using fecal transplantation to eradicate intestinal carr... | |||||||||||||||||||||||
Medical condition: Intestinal colonization with extended-spectrum beta-lactamse or carbapenemase producing enterobacteriaceae | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001396-16 | Sponsor Protocol Number: OP0595-6 | Start Date*: 2023-03-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Meiji Seika Pharma Co., Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Ur... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated ... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001618-41 | Sponsor Protocol Number: FERARO | Start Date*: 2020-04-14 | ||||||||||||||||
Sponsor Name:Guy's and St Thomas NHS Foundation Trust | ||||||||||||||||||
Full Title: FERARO: A prospective, randomised placebo controlled feasibility trial of Faecal microbiota Transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms | ||||||||||||||||||
Medical condition: Gastrointestinal colonisation and infection with Extended Spectrum Beta-lactamase (ESBL) producing Enetrobacteriales and Carbapenemase Producing Enetrobacteriales | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003562-20 | Sponsor Protocol Number: 2018-018 | Start Date*: 2023-03-07 | |||||||||||
Sponsor Name:INSTITUT PASTEUR | |||||||||||||
Full Title: A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients versus Tetracycline Derivative | |||||||||||||
Medical condition: Hidradenitis Suppurativa | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001997-18 | Sponsor Protocol Number: ACHN-490-007 | Start Date*: 2014-02-25 | |||||||||||
Sponsor Name:Achaogen, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared with Colistin in Patients with Infection due to Carbapenem-Resistant Enterobacteriace... | |||||||||||||
Medical condition: Bloodstream infections (BSI) and nosocomial pneumonia due to carbapenem-resistant Enterobacteriaceae (CRE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) ES (Prematurely Ended) IT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
